Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$35 Mln
P/E Ratio
--
P/B Ratio
2.9
Industry P/E
--
Debt to Equity
-0.28
ROE
-6.83 %
ROCE
261.48 %
Div. Yield
0 %
Book Value
--
EPS
-2.28
CFO
$-102.78 Mln
EBITDA
$-239.34 Mln
Net Profit
$-149.08 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
NRX Pharmaceuticals Inc (NRXP)
| -5.00 | 2.96 | -33.44 | -41.13 | 10.24 | -29.32 | -- |
|
BSE Sensex
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
NRX Pharmaceuticals Inc (NRXP)
| 372.20 | -58.56 | -76.78 | -80.41 | 130.19 | 3.92 | 5.34 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.70 | 10,593.45 | 21.84 | 23.13 | |
| 304.14 | 8,570.17 | 22.78 | 66.44 | |
| 28.24 | 10,589.59 | -- | -28.77 | |
| 106.58 | 10,559.67 | 32.44 | 14.16 |
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug... candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware. Address: 1201 Orange Street, Wilmington, DE, United States, 19801 Read more
Co-Founder, Chief Scientist Officer & Chairman
Dr. Jonathan C. Javitt M.D., M.P.H.
Co-Founder, Chief Scientist Officer & Chairman
Dr. Jonathan C. Javitt M.D., M.P.H.
Headquarters
Wilmington, DE
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of NRX Pharmaceuticals Inc (NRXP) stood at $ 4 Mln as on 31-Dec-24
The share price of NRX Pharmaceuticals Inc (NRXP) is $2.09 (NASDAQ) as of 30-Apr-2025 14:42 EDT. NRX Pharmaceuticals Inc (NRXP) has given a return of 10.24% in the last 3 years.
NRX Pharmaceuticals Inc (NRXP) has a market capitalisation of $ 35 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of NRX Pharmaceuticals Inc (NRXP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the NRX Pharmaceuticals Inc (NRXP) and enter the required number of quantities and click on buy to purchase the shares of NRX Pharmaceuticals Inc (NRXP).
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware. Address: 1201 Orange Street, Wilmington, DE, United States, 19801
The CEO & director of Dr. Jonathan C. Javitt M.D., M.P.H.. is NRX Pharmaceuticals Inc (NRXP), and CFO & Sr. VP is Dr. Jonathan C. Javitt M.D., M.P.H..
There is no promoter pledging in NRX Pharmaceuticals Inc (NRXP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| NRX Pharmaceuticals Inc (NRXP) | Ratios |
|---|---|
|
Return on equity(%)
|
143.76
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of NRX Pharmaceuticals Inc (NRXP) was $0 Mln.
$0.04
(
